Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | SYK | P43405 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.57 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | FOS | P01100 | 1/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354987 | 1.00 | ALDH1A1 (0.63) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL20891985 | 0.93 | ALDH1A1 (0.63) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL20875598 | 0.90 | ALDH1A1 (0.59) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL30873265 | 0.88 | ALDH1A1 (0.65) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL1521611 | 0.88 | ALDH1A1 (0.65) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL20875371 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL25829315 | 0.86 | ALDH1A1 (0.67) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL6631142 | 0.84 | ALDH1A1 (0.64) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL29545771 | 0.83 | ALDH1A1 (0.70) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL1521842 | 0.83 | ALDH1A1 (0.70) | ALDH1A1SYKMAPTSMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125944-A1 | COMPOUND CONTAINING HETEROCYCLIC RING | 正大天晴药业集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-111315747-B | Dihydropyrazolopyrimidine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | NEWAVE PHARMACEUTICAL INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| US-20220169646-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | NUVATION BIO INC. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022082174-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-2213673-B1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8329711-B2 | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2213673-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | ALDH1A1 755/4885SYK 1853/4885MAPT 4041/4885 |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | WEE1, WEE2, DPYD | ALDH1A1 2196/4885SYK 3488/4885MAPT 3968/4885 |
| US-20220169646-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | ALDH1A1 2869/4885SYK 2823/4885MAPT 4445/4885 |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE1, WEE2, CCNE1 | ALDH1A1 2764/4885SYK 3010/4885MAPT 4870/4885 |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | ALDH1A1 2869/4885SYK 2823/4885MAPT 4445/4885 |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | WEE1, WEE2, PHKG1 | ALDH1A1 1533/4885SYK 841/4885MAPT 3865/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | ALDH1A1 755/4885SYK 1853/4885MAPT 4041/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | ALDH1A1 755/4885SYK 1853/4885MAPT 4041/4885 |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | WEE1, WEE2, DPYD | ALDH1A1 2196/4885SYK 3488/4885MAPT 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.